Publications

Publications pour l'équipe Oncostat

Titre Publication Type Publication year Auteur
Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow journalArticle 2017 Blanchard, P.; Menard, C.; Frank, S. J.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
The frequency of cancer in France: Most recent data and trends journalArticle 2017 Ribassin-Majed, L.; Le-Teuff, G.; Hill, C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data journalArticle 2017 Yin, Jun; Paoletti, Xavier; Sargent, Daniel J; Mandrekar, Sumithra J
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification journalArticle 2017 Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J.
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials journalArticle 2017 Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study journalArticle 2017 Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice journalArticle 2017 Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M.
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors journalArticle 2017 Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C.
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort journalArticle 2017 Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A.
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study journalArticle 2017 Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L.
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? journalArticle 2017 Blanchard, P.; Bossi, A.; Fizazi, K.
Value of a short-term imaging follow-up after a benign result in a one-stop breast unit: Is it still useful? journalArticle 2017 Daroles, J.; Borget, I.; Suciu, V.; Mazouni, C.; Delaloge, S.; Balleyguier, C.
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study journalArticle 2017 Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment journalArticle 2017 Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C.
Diagnosis of systemic inflammatory diseases among patients admitted for acute pericarditis with pericardial effusion journalArticle 2017 Assayag, M.; Abbas, R.; Chanson, N.; Perozziello, A.; Ducrocq, G.; Alexandra, J. F.; Dossier, A.; Papo, T.; Sacre, K.
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? journalArticle 2017 Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial journalArticle 2017 Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L.
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial journalArticle 2017 Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C.
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium journalArticle 2017 Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X.
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients journalArticle 2017 Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C.
Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma journalArticle 2018 Grill, J.; Massimino, M.; Bouffet, E.; Azizi, A. A.; McCowage, G.; Canete, A.; Saran, F.; Le Deley, M. C.; Varlet, P.; Morgan, P. S.; Jaspan, T.; Jones, C.; Giangaspero, F.; Smith, H.; Garcia, J.; Elze, M. C.; Rousseau, R. F.; Abrey, L.; Hargrave, D.; Vassal, G.
Robotic Prophylactic Nipple-Sparing Mastectomy with Immediate Prosthetic Breast Reconstruction: A Prospective Study journalArticle 2018 Sarfati, B.; Struk, S.; Leymarie, N.; Honart, J. F.; Alkhashnam, H.; Tran de Fremicourt, K.; Conversano, A.; Rimareix, F.; Simon, M.; Michiels, S.; Kolb, F.
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer journalArticle 2018 Criscitiello, C.; Bayar, M. A.; Curigliano, G.; Symmans, F. W.; Desmedt, C.; Bonnefoi, H.; Sinn, B.; Pruneri, G.; Vicier, C.; Pierga, J. Y.; Denkert, C.; Loibl, S.; Sotiriou, C.; Michiels, S.; André, F.
Peritoneal Metastases from Colorectal Cancer: Treatment Principles and Perspectives journalArticle 2018 Goere, D.; Sourrouille, I.; Gelli, M.; Benhaim, L.; Faron, M.; Honore, C.
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy journalArticle 2018 Slimano, F.; Netzer, F.; Borget, I.; Lemare, F.; Besse, B.
A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial journalArticle 2018 Lui, Gabrielle; Treluyer, Jean-Marc; Fresneau, Brice; Piperno-Neumann, Sophie; Gaspar, Nathalie; Corradini, Nadège; Gentet, Jean-Claude; Marec Berard, Perrine; Laurence, Valérie; Schneider, Pascale; Entz-Werle, Natacha; Pacquement, Hélène; Millot, Frédéric; Taque, Sophie; Freycon, Claire; Lervat, Cyril; Le Deley, Marie Cécile; Mahier Ait Oukhatar, Céline; Brugieres, Laurence; Le Teuff, Gwénaël; Bouazza, Naïm; Sarcoma Group of UNICANCER
All simulation models of breast cancer are wrong but some are useful journalArticle 2018 Michiels, S.; Delaloge, S.
Evaluation of Treatment Effect with Paired Failure Times in a Single-Arm Phase II Trial in Oncology journalArticle 2018 Texier, M.; Rotolo, F.; Ducreux, M.; Bouché, O.; Pignon, J. P.; Michiels, S.
biospear: an R package for biomarker selection in penalized Cox regression journalArticle 2018 Ternes, N.; Rotolo, F.; Michiels, S.
Sentinel node biopsy in early oral squamous cell carcinomas: Long-term follow-up and nodal failure analysis journalArticle 2018 Moya-Plana, A.; Aupérin, A.; Guerlain, J.; Gorphe, P.; Casiraghi, O.; Mamelle, G.; Melkane, A.; Lumbroso, J.; Janot, F.; Temam, S.
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials journalArticle 2018 Early Breast Cancer Trialists' Collaborative, Group